Latest Stories for GlycoMimetics, Inc. Promoted Stories,2015-04-13:/organization/651082015-04-13T06:49:11-07:00<![CDATA[GlycoMimetics Provides Update on Pfizer’s Plans to Initiate Phase 3 Trial with Rivipansel in Mid-2015]]>,2015-04-07:3731852015-04-07T04:00:52-07:00logo

– GlycoMimetics to receive $20 million milestone payment upon dosing of first patient in trial – ]]>
<![CDATA[GlycoMimetics to Present First Preclinical Data on E-selectin-CXCR4 Dual Antagonist for Cancer Indications at AACR Annual Meeting 2015]]>,2015-03-19:3695192015-03-19T06:30:16-07:00logo

<![CDATA[GlycoMimetics Reports Fourth Quarter and Year-End 2014 Results]]>,2015-03-16:3638742015-03-16T13:30:34-07:00logo

Year-End Cash and Cash Equivalents of $55.2 million ]]>
<![CDATA[GlycoMimetics Announces Publication of Phase 2 Data for Rivipansel in Sickle Cell Disease]]>,2015-03-03:3473362015-03-03T06:06:10-08:00logo

- Data underscores potential to provide meaningful clinical benefits and pharmacoeconomic impacts for patients in vaso-occlusive crisis - ]]>
<![CDATA[GlycoMimetics to Present at Two Investor Conferences in March]]>,2015-02-26:3515232015-02-26T06:04:47-08:00logo

<![CDATA[GlycoMimetics to Present at 17th Annual BIO CEO & Investor Conference]]>,2015-02-03:3410942015-02-03T06:05:48-08:00logo

<![CDATA[GlycoMimetics Highlights Potential Therapeutic Benefits of Its Novel E-Selectin Antagonist at 56th ASH Annual Meeting]]>,2014-12-09:3306182014-12-09T06:09:01-08:00logo

Preclinical Data Shared Through Four Oral Presentations and One Poster Focus on the Potential Role of GMI-1271 in Treating Blood Cancers and Coagulation Disorders Biomarker Data from Phase 2 Study of Rivipansel Also Displayed via Poster Session at ASH Meeting ]]>
<![CDATA[University of Michigan to Study GlycoMimetics’ GMI-1271 as Potential Treatment for Serious Blood-Clotting Disorder]]>,2014-12-04:3165292014-12-04T06:04:07-08:00logo

- National Heart Lung and Blood Institute grant is funding University of Michigan Phase 1 trial ]]>
<![CDATA[GlycoMimetics Announces Positive Top-Line Results from Phase 1 Study of GMI-1271 in Healthy Volunteers]]>,2014-11-17:3187262014-11-17T13:00:13-08:00logo

- E-selectin antagonist GMI-1271 to advance to chemo-combination study in AML - ]]>
<![CDATA[GlycoMimetics to Present at Stifel Healthcare Conference 2014]]>,2014-11-12:3299782014-11-12T06:06:37-08:00logo

<![CDATA[GlycoMimetics E-selectin and Sickle Cell Data to Be Highlighted at 56th ASH Annual Meeting]]>,2014-11-06:3316042014-11-06T06:33:13-08:00logo

Preclinical data on GMI-1271 in four oral presentations and one poster focus on blood cancers and coagulation disorders New data for rivipansel, sickle cell investigational drug candidate, show effects on biomarkers ]]>
<![CDATA[GlycoMimetics Reports Third Quarter 2014 Results]]>,2014-10-31:3161892014-10-31T06:15:07-07:00logo

<![CDATA[GlycoMimetics to Present at 34th Annual Canaccord Genuity Global Growth Conference]]>,2014-08-08:2899912014-08-08T07:39:10-07:00logo

<![CDATA[GlycoMimetics Reports Second Quarter 2014 Results]]>,2014-07-31:2873332014-07-31T13:00:38-07:00logo

<![CDATA[GlycoMimetics Appoints Mark A. Goldberg, M.D. to Board of Directors]]>,2014-07-10:2805782014-07-10T06:08:46-07:00logo

- Dr. Goldberg Brings Perspective as Medical Oncologist and Hematologist and Extensive Biopharmaceutical Regulatory Experience to GlycoMimetics Board - ]]>